These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 33809582)

  • 1. Neuroendocrine-Related Circulating Transcripts in Small-Cell Lung Cancers: Detection Methods and Future Perspectives.
    Muscarella LA; Mazza T; Fabrizio FP; Sparaneo A; D'Alessandro V; Tancredi A; Trombetta D; Centra F; Muscarella SP; Di Micco CM; Rossi A
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33809582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SCG3 transcript in peripheral blood is a prognostic biomarker for REST-deficient small cell lung cancer.
    Moss AC; Jacobson GM; Walker LE; Blake NW; Marshall E; Coulson JM
    Clin Cancer Res; 2009 Jan; 15(1):274-83. PubMed ID: 19118055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Characterization of Circulating Tumor Cells Enriched by A Microfluidic Platform in Patients with Small-Cell Lung Cancer.
    Obermayr E; Agreiter C; Schuster E; Fabikan H; Weinlinger C; Baluchova K; Hamilton G; Hochmair M; Zeillinger R
    Cells; 2019 Aug; 8(8):. PubMed ID: 31412616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of four DLL3 antibodies performance in high grade neuroendocrine lung tumor samples and cell cultures.
    Brcic L; Kuchler C; Eidenhammer S; Pabst D; Quehenberger F; Gazdar AF; Popper H
    Diagn Pathol; 2019 May; 14(1):47. PubMed ID: 31109352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) and evaluation of their clinical relevance during front-line treatment.
    Messaritakis I; Nikolaou M; Koinis F; Politaki E; Koutsopoulos A; Lagoudaki E; Vetsika EK; Georgoulias V; Kotsakis A
    Lung Cancer; 2019 Sep; 135():33-39. PubMed ID: 31447000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of progastrin-releasing peptide and gastrin-releasing peptide receptor mRNA transcripts in tumor cells of patients with small cell lung cancer.
    Uchida K; Kojima A; Morokawa N; Tanabe O; Anzai C; Kawakami M; Eto Y; Yoshimura K
    J Cancer Res Clin Oncol; 2002 Dec; 128(12):633-40. PubMed ID: 12474049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ProGRP: a new biomarker for small cell lung cancer.
    Molina R; Filella X; Augé JM
    Clin Biochem; 2004 Jul; 37(7):505-11. PubMed ID: 15234231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progastrin-releasing peptide as a diagnostic and therapeutic biomarker of small cell lung cancer.
    Oh HJ; Park HY; Kim KH; Park CK; Shin HJ; Lim JH; Kwon YS; Oh IJ; Kim YI; Lim SC; Kim YC; Kim SH; Shin MG
    J Thorac Dis; 2016 Sep; 8(9):2530-2537. PubMed ID: 27747005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. POU domain transcription factor BRN2 is crucial for expression of ASCL1, ND1 and neuroendocrine marker molecules and cell growth in small cell lung cancer.
    Ishii J; Sato H; Sakaeda M; Shishido-Hara Y; Hiramatsu C; Kamma H; Shimoyamada H; Fujiwara M; Endo T; Aoki I; Yazawa T
    Pathol Int; 2013 Mar; 63(3):158-68. PubMed ID: 23530560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pro-gastrin-releasing peptide (ProGRP) as a biomarker in small-cell lung cancer diagnosis, monitoring and evaluation of treatment response.
    Wojcik E; Kulpa JK
    Lung Cancer (Auckl); 2017; 8():231-240. PubMed ID: 29238236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme-linked immunosorbent assay of pro-gastrin-releasing peptide for small cell lung cancer patients in comparison with neuron-specific enolase measurement.
    Yamaguchi K; Aoyagi K; Urakami K; Fukutani T; Maki N; Yamamoto S; Otsubo K; Miyake Y; Kodama T
    Jpn J Cancer Res; 1995 Jul; 86(7):698-705. PubMed ID: 7559089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating tumor cell and cell-free RNA capture and expression analysis identify platelet-associated genes in metastatic lung cancer.
    Beck TN; Boumber YA; Aggarwal C; Pei J; Thrash-Bingham C; Fittipaldi P; Vlasenkova R; Rao C; Borghaei H; Cristofanilli M; Mehra R; Serebriiskii I; Alpaugh RK
    BMC Cancer; 2019 Jun; 19(1):603. PubMed ID: 31215484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).
    Furuta M; Sakakibara-Konishi J; Kikuchi H; Yokouchi H; Nishihara H; Minemura H; Harada M; Yamazaki S; Akie K; Fujita Y; Takamura K; Kojima T; Harada T; Minami Y; Watanabe N; Oizumi S; Suzuki H; Nishimura M; Dosaka-Akita H; Isobe H;
    Oncologist; 2019 Nov; 24(11):e1172-e1179. PubMed ID: 31068386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive and prognostic value of folate receptor-positive circulating tumor cells in small cell lung cancer patients treated with first-line chemotherapy.
    Shen J; Zhao J; Jiang T; Li X; Zhao C; Su C; Zhou C
    Oncotarget; 2017 Jul; 8(30):49044-49052. PubMed ID: 28467771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of pro-gastrin releasing peptide promotes the cell proliferation and progression in small cell lung cancer.
    Gong Z; Lu R; Xie S; Jiang M; Liu K; Xiao R; Shen J; Wang Y; Guo L
    Biochem Biophys Res Commun; 2016 Oct; 479(2):312-318. PubMed ID: 27639644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Harnessing DLL3 inhibition: From old promises to new therapeutic horizons.
    Cortinovis DL; Colonese F; Abbate MI; Sala L; Meazza Prina M; Cordani N; Sala E; Canova S
    Front Med (Lausanne); 2022; 9():989405. PubMed ID: 36530878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC).
    Shibayama T; Ueoka H; Nishii K; Kiura K; Tabata M; Miyatake K; Kitajima T; Harada M
    Lung Cancer; 2001 Apr; 32(1):61-9. PubMed ID: 11282430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Establishment of cut-off value of serum pro-gastrin-releasing peptide for diagnosis of small cell lung cancer and evaluation on the clinical diagnosis efficiency].
    Shen D; Han BB; Chen F; Wei BJ; Cui CJ; Wang GJ; Cui W
    Zhonghua Yi Xue Za Zhi; 2017 Sep; 97(34):2657-2662. PubMed ID: 28910952
    [No Abstract]   [Full Text] [Related]  

  • 19. [Utility of NSE, ProGRP and LDH in Diagnosis and Treatment
in Patients with Small Cell Lung Cancer].
    Peng Y; Wang Y; Li J; Hao X; Hu X
    Zhongguo Fei Ai Za Zhi; 2016 Sep; 19(9):590-4. PubMed ID: 27666548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges.
    Leonetti A; Facchinetti F; Minari R; Cortellini A; Rolfo CD; Giovannetti E; Tiseo M
    Cell Oncol (Dordr); 2019 Jun; 42(3):261-273. PubMed ID: 30968324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.